ArticleInternational journal of obesity (2005)2015
Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events.
Article in International journal of obesity (2005), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02498431 (Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention
Who cites it
48 citing papers in PubMed, 110 citations in OpenAlex.
- Role of irisin in physical activity, sarcopenia-associated type 2 diabetes, and cardiovascular complications.World journal of methodology · 2025Review
- The Role of Selected Myokines in the Development of Cardiovascular Diseases, and Their Involvement in Developing Heart Failure in Rheumatoid Arthritis Patients.International journal of molecular sciences · 2025Review
- Alterations of the Adipo-Myokine Irisin in Sepsis and Septic Shock: Diagnostic and Prognostic Implications.Biomolecules · 2024Article
- Review
- Non-Thyroidal Illness in Chronic Renal Failure: Triiodothyronine Levels and Modulation of Extra-Cellular Superoxide Dismutase (ec-SOD).Antioxidants (Basel, Switzerland) · 2024Article
- Serum irisin correlates to the severity of acute myocardial infarction and predicts the postoperative major adverse cardiovascular events.Biomolecules & biomedicine · 2023Article
- Irisin as a Novel Biomarker of Subclinical Atherosclerosis in Severe Obesity.International journal of molecular sciences · 2023Observational
- Irisin and Cardiometabolic Disorders in Obesity: A Systematic Review.International journal of inflammation · 2023Review
- Association Between Serum Irisin Levels and ST-Segment Elevation Myocardial Infarction.International journal of general medicine · 2023Article
- Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease.Journal of clinical medicine · 2022Article
- Molecular basis of acute coronary syndrome.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).Frontiers in physiology · 2022Review
- Cardiometabolic Effects of Irisin in Patients with End-Stage Renal Disease on Regular Hemo- or Peritoneal Dialysis.Blood purification · 2022Article
- Review
- Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction.Anatolian journal of cardiology · 2021Article
- The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease.Frontiers in endocrinology · 2021Review
- Irisin: A Promising Target for Ischemia-Reperfusion Injury Therapy.Oxidative medicine and cellular longevity · 2021Review
- Adropin and Irisin Deficiencies Are Associated With Presence of Diagonal Earlobe Crease in CAD Patients.Frontiers in cardiovascular medicine · 2021Article
- Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes.Disease markers · 2021Review
- Irisin and Autophagy: First Update.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIrisin is a newly discovered myokine, associated with 'browning' of the white adipose tissue, obesity, insulin resistance and metabolic syndrome. The purpose of this study is to evaluate circulating irisin as a predictor of acute coronary syndromes (ACSs) and major adverse cardiovascular events (MACE).
methodsSub-study 1: a case-control study, nested within the Veteran's Affairs Normative Ageing Study, evaluating circulating irisin levels in 88 ACS cases and 158 age- and sampling year-matched controls, as a predictor of ACS. Sub-study 2: a prospective cohort study, where 103 participants with established coronary artery disease were stratified by circulating irisin levels at the time they received percutaneous coronary interventions (PCIs) and were followed for the development of MACE.
resultsStudy 1: there was no association between irisin levels and ACS in otherwise healthy individuals (odds ratio: 1.00 95% confidence interval: (0.99-1.00)). Study 2: the incidence of MACE was significantly lower in the first irisin tertile compared with the second and third (incidence rate 0 vs 0.92 (0.51-1.61) vs 0.57 (0.28-1.14) events per 1000 person-days; P < 0.01). This was primarily driven by the lower incidence of unstable angina (incidence rate 0 vs 0.61 (0.31-1.22) vs 0.43 (0.19-0.96) per 1000 person-days; P = 0.01).
conclusionThis is the first study to date that demonstrates that, although circulating irisin levels do not predict the development of ACS in healthy individuals, increased irisin levels are associated with the development of MACE in patients with established coronary artery disease after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.